This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Surmodics (SRDX) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Surmodics' (SRDX) fiscal first-quarter earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.
SurModics (SRDX) Surpasses Q1 Earnings Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 266.67% and -0.89%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: SurModics (SRDX) Q1 Earnings Expected to Decline
by Zacks Equity Research
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: SurModics (SRDX) Q1 Earnings Expected to Decline
by Zacks Equity Research
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Surmodics (SRDX) Stock for Now
by Zacks Equity Research
Surmodics (SRDX) is gaining from continued strength at Medical Devices unit and persistent efforts to boost R&D functionalities. However, weak performance at Surmodics' IVD unit remains a concern.
Here's Why You Should Hold on to Surmodics (SRDX) Stock Now
by Zacks Equity Research
Surmodics (SRDX) is gaining from continued strength at Medical Devices unit and persistent efforts to boost R&D functionalities. However, weak performance at Surmodics' IVD unit remains a concern.
Surmodics (SRDX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Surmodics (SRDX) continues to gain from core Medical Devices unit, which saw significant contribution from the SurVeil deal with Abbott in Q4.
SurModics (SRDX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 5.71% and 8.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
LabCorp (LH) Q3 Earnings Surpass Estimates, Tapers View
by Zacks Equity Research
LabCorp (LH) impresses investors with third-quarter 2019 results on the robust performance of the Covance Drug Development segment.
Here's Why You Should Hold on to Abbott (ABT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Abbott's (ABT) performance.
ResMed Upgrades Nasal Care by Introducing Cradle CPAP Mask
by Zacks Equity Research
ResMed (RMD) revolutionizes sleep apnea treatment by introducing a hassle-free and easy-to-use mask.
Medical Products Industry Outlook: Prospects Seem Promising
by Trina Mukherjee
Growth prospects look bright for the Zacks Medical Products industry, thanks to AI, Medical Mechatronics and Robotics and rampant M&As.
Here's Why You Should Hold on to Chemed (CHE) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about Chemed's (CHE) performance.
Organigram (OGI) Catches Eye: Stock Jumps 8.6%
by Zacks Equity Research
Organigram (OGI) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Here's Why You Should Invest in Surmodics (SRDX) Stock Now
by Zacks Equity Research
Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.
Top Ranked Momentum Stocks to Buy for September 26th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, September 26th
Will SurModics (SRDX) Gain on Rising Earnings Estimates?
by Zacks Equity Research
SurModics (SRDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Wall Street Bulls Roaring Despite Slowdown Fears: 5 Top Picks
by Nalak Das
Year to date, the performance on Wall Street is projecting a glorious picture with no end to the bull run in sight, at least this year.
Stryker's Mobius Imaging Buyout to Boost Its Spine Division
by Zacks Equity Research
Stryker (SYK) expects the buyout to remain neutral to its 2019 earnings.
Here's Why You Should Invest in Surmodics (SRDX) Stock Now
by Zacks Equity Research
Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.
Haemonetics (HAE) Beats on Q1 Earnings, Raises '19 EPS View
by Zacks Equity Research
Haemonetics (HAE) Q1 performance by all business sections has been impressive, except for BloodCenter.
BioScrip Closes Option Care Merger, Incurs Wider Q2 Loss
by Zacks Equity Research
With the conclusion of BioScrip (BIOS)-Option Care consolidation, the newly formed company gets its new name Option Care Health, Inc. under the ticker symbol BIOS.
Orthofix Medical (OFIX) Beats on Q2 Earnings, Margins Down
by Zacks Equity Research
Orthofix Medical's (OFIX) Q2 performance across all business segments has been commendable, except for spinal implants.
Surging Earnings Estimates Signal Upside for SurModics (SRDX) Stock
by Zacks Equity Research
SurModics (SRDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Surmodics (SRDX) Q3 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Surmodics (SRDX) continues to gain from core Medical Devices unit, which saw significant contribution from the SurVeil deal with Abbott in Q3.